[1]
Lescano, A., Atamañuk, N., Bortman, G., Cáneva, J., Diez, M., Giacomi, G., Lema, L. and Perna, E.R. 2022. Long-term effect of subcutaneous treprostinil in patients with pulmonary hypertension: rationale and design of the phase IV, multicentre, observational TREPAR-HP study. International Journal of Clinical Trials. 9, 3 (Jul. 2022), 174–182. DOI:https://doi.org/10.18203/2349-3259.ijct20221868.